FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma By Ogkologos - February 4, 2026 67 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BRUIN-CLL-321 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK June 15, 2023 Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... November 20, 2019 Understanding the Risk of Second Cancers After CAR T-Cell Therapy August 13, 2024 Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... January 5, 2023 Load more HOT NEWS EMA Recommends Extension of Indications for Lorlatinib Thank you! 120 years of discovery: 10 ways we’ve changed the story for... Autumn and Letting Go
